These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

493 related items for PubMed ID: 28825374

  • 1. Nivolumab-induced aplastic anemia: A case report and literature review.
    Comito RR, Badu LA, Forcello N.
    J Oncol Pharm Pract; 2019 Jan; 25(1):221-225. PubMed ID: 28825374
    [Abstract] [Full Text] [Related]

  • 2. Unexpected serious aplastic anemia from PD-1 inhibitors: beyond what we know.
    Filetti M, Giusti R, Di Napoli A, Iacono D, Marchetti P.
    Tumori; 2019 Dec; 105(6):NP48-NP51. PubMed ID: 31221037
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Immunotherapy-associated autoimmune hemolytic anemia.
    Khan U, Ali F, Khurram MS, Zaka A, Hadid T.
    J Immunother Cancer; 2017 Dec; 5():15. PubMed ID: 28239468
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. New onset diabetes with ketoacidosis following nivolumab immunotherapy: A case report and review of literature.
    Delasos L, Bazewicz C, Sliwinska A, Lia NL, Vredenburgh J.
    J Oncol Pharm Pract; 2021 Apr; 27(3):716-721. PubMed ID: 32723064
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Progressive Multifocal Leukoencephalopathy after Treatment with Nivolumab.
    Martinot M, Ahle G, Petrosyan I, Martinez C, Gorun DM, Mohseni-Zadeh M, Fafi-Kremer S, Tebacher-Alt M.
    Emerg Infect Dis; 2018 Aug; 24(8):1594-1596. PubMed ID: 30016251
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: potential role of Th1-dominant immune response in immune-related adverse events: two case reports.
    Yoshino K, Nakayama T, Ito A, Sato E, Kitano S.
    BMC Cancer; 2019 Oct 29; 19(1):1019. PubMed ID: 31664934
    [Abstract] [Full Text] [Related]

  • 15. Immune Thrombocytopenia Induced by Nivolumab in a Metastatic Non-Small Cell Lung Cancer Patient.
    Karakas Y, Yuce D, Kılıckap S.
    Oncol Res Treat; 2017 Oct 29; 40(10):621-622. PubMed ID: 28950270
    [No Abstract] [Full Text] [Related]

  • 16. Nivolumab for the treatment of Japanese patients with advanced metastatic non-small cell lung cancer: a review of clinical trial evidence for efficacy and safety.
    Hida T.
    Ther Adv Respir Dis; 2018 Oct 29; 12():1753466618801167. PubMed ID: 30249170
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Hyperprogression after nivolumab for melanoma: A case report.
    Yilmaz M, Akovali B.
    J Oncol Pharm Pract; 2020 Jan 29; 26(1):244-251. PubMed ID: 31068087
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.